Cargando…

Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan

INTRODUCTION: Several treatment guidelines for Parkinson’s disease (PD) had been proposed in recent decades. The aim of current study was to investigate the initial medication utilized in newly diagnosed PD subjects in Taiwan during an eleven-year period. METHODS: A total of 7,550 patients with newl...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yi-Jen, Liao, Yi-Chu, Lin, Ching-Heng, Chang, Ming-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164642/
https://www.ncbi.nlm.nih.gov/pubmed/25222829
http://dx.doi.org/10.1371/journal.pone.0107465
_version_ 1782334978585001984
author Guo, Yi-Jen
Liao, Yi-Chu
Lin, Ching-Heng
Chang, Ming-Hong
author_facet Guo, Yi-Jen
Liao, Yi-Chu
Lin, Ching-Heng
Chang, Ming-Hong
author_sort Guo, Yi-Jen
collection PubMed
description INTRODUCTION: Several treatment guidelines for Parkinson’s disease (PD) had been proposed in recent decades. The aim of current study was to investigate the initial medication utilized in newly diagnosed PD subjects in Taiwan during an eleven-year period. METHODS: A total of 7,550 patients with newly diagnosed Parkinsonism were retrospectively enrolled from the National Health Insurance Research Database of Taiwan from 2000 to 2010. After excluding patients at risk of secondary or atypical Parkinsonism, those never receiving medication or having incomplete data, 1,645 subjects were included. The participants were then divided into four treating regimen groups, namely levodopa (LD) only group, dopamine agonist (DA) only group, LD+DA group, and No-LD, No-DA group. The demographic data and medication retention rate were compared across the four treatment groups. RESULTS: LD only and No-LD, No-DA regimens were the main initial choice of PD treatment in Taiwan. LD containing drugs were more often prescribed to the elderly population than the other two treatment regimens, while No-LD, No-DA medication was the major initial choice for younger patients. DA only regimen occupied only 3–4% of the initial PD prescriptions and was given predominantly by neurologists. Over the eleven-year period, there is a trend for the middle-aged population to receive medication containing LD as initial treatment. The one year retention rate of anti-Parkinsonism medication was around 30–50% in our population. Age, polypharmacy, change of one-year daily levodopa equivalent dosage and newly onset of dementia, stroke and psychiatric diseases all affect drug compliance in PD patients. CONCLUSIONS: This is the first long-term study to explore initial pharmacotherapies in an Asian PD population. We hope to provide evidence for adjusting government policies and public education of physicians and PD patients in the future.
format Online
Article
Text
id pubmed-4164642
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41646422014-09-19 Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan Guo, Yi-Jen Liao, Yi-Chu Lin, Ching-Heng Chang, Ming-Hong PLoS One Research Article INTRODUCTION: Several treatment guidelines for Parkinson’s disease (PD) had been proposed in recent decades. The aim of current study was to investigate the initial medication utilized in newly diagnosed PD subjects in Taiwan during an eleven-year period. METHODS: A total of 7,550 patients with newly diagnosed Parkinsonism were retrospectively enrolled from the National Health Insurance Research Database of Taiwan from 2000 to 2010. After excluding patients at risk of secondary or atypical Parkinsonism, those never receiving medication or having incomplete data, 1,645 subjects were included. The participants were then divided into four treating regimen groups, namely levodopa (LD) only group, dopamine agonist (DA) only group, LD+DA group, and No-LD, No-DA group. The demographic data and medication retention rate were compared across the four treatment groups. RESULTS: LD only and No-LD, No-DA regimens were the main initial choice of PD treatment in Taiwan. LD containing drugs were more often prescribed to the elderly population than the other two treatment regimens, while No-LD, No-DA medication was the major initial choice for younger patients. DA only regimen occupied only 3–4% of the initial PD prescriptions and was given predominantly by neurologists. Over the eleven-year period, there is a trend for the middle-aged population to receive medication containing LD as initial treatment. The one year retention rate of anti-Parkinsonism medication was around 30–50% in our population. Age, polypharmacy, change of one-year daily levodopa equivalent dosage and newly onset of dementia, stroke and psychiatric diseases all affect drug compliance in PD patients. CONCLUSIONS: This is the first long-term study to explore initial pharmacotherapies in an Asian PD population. We hope to provide evidence for adjusting government policies and public education of physicians and PD patients in the future. Public Library of Science 2014-09-15 /pmc/articles/PMC4164642/ /pubmed/25222829 http://dx.doi.org/10.1371/journal.pone.0107465 Text en © 2014 Guo et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Guo, Yi-Jen
Liao, Yi-Chu
Lin, Ching-Heng
Chang, Ming-Hong
Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan
title Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan
title_full Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan
title_fullStr Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan
title_full_unstemmed Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan
title_short Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan
title_sort initial medication in patients of newly diagnosed parkinson’s disease in taiwan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164642/
https://www.ncbi.nlm.nih.gov/pubmed/25222829
http://dx.doi.org/10.1371/journal.pone.0107465
work_keys_str_mv AT guoyijen initialmedicationinpatientsofnewlydiagnosedparkinsonsdiseaseintaiwan
AT liaoyichu initialmedicationinpatientsofnewlydiagnosedparkinsonsdiseaseintaiwan
AT linchingheng initialmedicationinpatientsofnewlydiagnosedparkinsonsdiseaseintaiwan
AT changminghong initialmedicationinpatientsofnewlydiagnosedparkinsonsdiseaseintaiwan